{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"ORR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- \\< 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0\\*10\\^9/L and/or platelets ≥100\\*10\\^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), \\< 5% of blasts contain auer rods, peripheral blood- neutrophils \\<1.0\\*10\\^9/L and/or platelets \\<100\\*10\\^9/L, no evidence of extramedullary disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all the participants who had received at least 1 dose of study drug. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the start of the treatment until disease progression (maximum up to 19.4 months)","title":"ORR for Hematologic Tumors: Acute Myeloid Leukemia","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}